辛伐他汀和氟伐他汀对冠心病患者C反应蛋白的影响

Effects of Simvastatin and Fluvastatin on the plasma levels of C-reactive protein in patient with coronary heart disease

目的 :探讨辛伐他汀和氟伐他汀对冠心病 (CHD)患者血浆 C反应蛋白 (CRP)水平的影响。方法 :将 15 6例CHD患者随机分为 3组 ,分别给予口服安慰剂 (A组 )、辛伐他汀 (B组 )、氟伐他汀 (C组 ) ,采用散射光比浊法测定 3组患者用药前及用药后 4 ,6 ,8周血浆的 CRP浓度、总胆固醇 (TC)浓度。结果 :1B组及 C组患者用药后 4 ,6 ,8周 ,血浆 CRP水平均明显低于 A组 (P<0 .0 5 ,P<0 .0 1,P<0 .0 1)。 2 B组及 C组患者血浆 CRP水平在用药后 4 ,6 ,8周呈逐渐下降趋势 ,与用药前相比 ,均有显著性差异 (P<0 .0 5 ,P<0 .0 1,P<0 .0 1)。 3B组及 C组患者血浆 TC水平在用药后 4 ,6 ,8周呈逐渐下降趋势 ,与用药前相比 ,均有显著性差异 (P<0 .0 5 ,P<0 .0 5 ,P<0 .0 1)。 4 B组及 C组患者的血浆 CRP水平的降低与血浆 TC水平的降低不相关 (P>0 .0 5 )。结论 :辛伐他汀和氟伐他汀降低 CHD患者血脂的同时 。

AIM: To explore the effects of Simvastatin and Fluvastatin on the plasma levels of C reactive protein (CRP) in patient with coronary heart disease(CHD). METHODS: 156 CHD patients were randomly divided into three groups:Group A treated with placebo,Group B with simvastatin and Group C with fluvastatin,and their plasma CRP and total cholesterol(TC) levels were measured by nephelometry before and 4,6 and 8 weeks after the treatment. RESULTS: ①4,6 and 8 weeks after the treatment,the plasma CRP levels of Groups B and C were significantly lower than those of Group A(P<0.05,P<0.01 and P<0.01 respectively). ②Both B group and C goup were treated after 4 weeks,6 weeks,8 weeks,their plasma levels of CRP were significantly lower than that before treated(respectively P<0.05,P<0.01,P<0.01). ③In Groups B and C,the plasma TC levels were markedly lower 4,6 and 8 weeks after the treatment than before the treatment (P<0.05,P<0.05 and P<0.01 respectively). ④There was no correlation between the decrease of CRP levels and that of TC levels in Groups B and C(P>0.05). CONCLUSION: Lipid lowering therapy with simvastatin and fluvastatin have beneficial effects on antiinflammation.